Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211897 · ClinicalTrials.gov registry record
Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation
A clinical trial of Agitation,Psychomotor, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- 737
- Enrollment target
- 1
- Study location
NCT03211897: Completed study of Agitation,Psychomotor, sponsored by Hennepin Healthcare Research Institute.
NCT03211897 is a study of Agitation,Psychomotor that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 737 participants, above the 212-participant average among 5 other Agitation,Psychomotor trials with a reported enrollment target (248% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03211897, a study of Agitation,Psychomotor, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- 737 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research investigation is to conduct a prospective observational study of the comparative efficacy of haloperidol versus olanzapine versus midazolam versus ziprasidone for the treatment of acute undifferentiated agitation in the emergency department.
Primary Outcome
Patients score on a previously validated agitation scale called the AMSS ADDENDUM: The primary outcome for this study was changed prior to study initiation to the proportion of patients adequately sedated at 15 minutes (defined as AMSS \< 1). This addendum was methodologically necessary to account for the ordinal, non-normal distribution of this data.
Conditions Studied
Interventions
- DRUG Haloperidol Injection
- DRUG Ziprasidone Injection
- DRUG OLANZapine Injection
- DRUG Midazolam injection
Study Locations (1)
Minnesota
- Hennepin County Medical Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 737 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2017-10-01 |
What the finished NCT03211897 record still lists
NCT03211897 is an observational study that tracks outcomes without assigning an intervention. The registered 737 participants enrollment target is mid-sized for trials with a published cap, above the 212-participant average among 5 other Agitation,Psychomotor trials with a reported enrollment target (248% higher).
The record links to 1 condition, with Agitation,Psychomotor appearing as the primary indexed condition, and to 4 interventions - of which Haloperidol Injection is the first listed.
NCT03211897 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03211897 about?
NCT03211897 is a clinical study titled "Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation". The goal of this research investigation is to conduct a prospective observational study of the comparative efficacy of haloperidol versus olanzapine versus midazolam versus ziprasidone for the treatment of acute undifferentiated agitation in the emergency department.
What is the current status of trial NCT03211897?
This trial is currently completed. The enrollment target is 737 participants. The study started on 2017-06-15. Estimated completion is 2017-10-01.
What conditions does trial NCT03211897 study?
This clinical trial studies the following conditions: Agitation,Psychomotor.
What interventions are being tested in trial NCT03211897?
The interventions under investigation include: Haloperidol Injection (DRUG), Ziprasidone Injection (DRUG), OLANZapine Injection (DRUG), Midazolam injection (DRUG).
Who is sponsoring clinical trial NCT03211897?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03211897 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Agitation,Psychomotor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial on Agitation in Alzheimer's Dementia
RECRUITING · Phase 2
-
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
RECRUITING · Early Phase 1
-
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
RECRUITING · NA
-
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
COMPLETED · Phase 3
-
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796141 · 736 participants · NA
Becoming United in Lifestyle Decisions
- NCT03723928 · 739 participants · NA
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI